Filing Details
- Accession Number:
- 0001209191-20-015666
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2020-03-03 18:59:31
- Reporting Period:
- 2020-03-03
- Accepted Time:
- 2020-03-03 18:59:31
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1787297 | Passage Bio Inc. | PASG | () | 4 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1341382 | N James Topper | 601 Union Street Suite 3200 Seattle WA 98101 | No | No | Yes | No | |
| 1720320 | Frazier Life Sciences Ix, L.p. | 601 Union Street Suite 3200 Seattle WA 98101 | No | No | Yes | No | |
| 1782789 | Fhmls Ix, L.p. | 601 Union Street Suite 3200 Seattle WA 98101 | No | No | Yes | No | |
| 1782791 | Fhmls Ix, L.l.c. | 601 Union Street Suite 3200 Seattle WA 98101 | No | No | Yes | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2020-03-03 | 2,977,242 | $0.00 | 2,977,242 | No | 4 | C | Direct | |
| Common Stock | Acquisiton | 2020-03-03 | 1,049,175 | $0.00 | 4,026,417 | No | 4 | C | Direct | |
| Common Stock | Acquisiton | 2020-03-03 | 432,802 | $0.00 | 4,459,219 | No | 4 | C | Direct | |
| Common Stock | Acquisiton | 2020-03-03 | 550,000 | $18.00 | 5,009,219 | No | 4 | P | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | C | Direct | |
| No | 4 | C | Direct | |
| No | 4 | C | Direct | |
| No | 4 | P | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Series A-1 Preferred Stock | Disposition | 2020-03-03 | 2,977,242 | $0.00 | 2,977,242 | $0.00 |
| Common Stock | Series A-2 Preferred Stock | Disposition | 2020-03-03 | 1,049,175 | $0.00 | 1,049,175 | $0.00 |
| Common Stock | Series B Preferred Stock | Disposition | 2020-03-03 | 432,802 | $0.00 | 432,802 | $0.00 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 0 | No | 4 | C | Direct | ||
| 0 | No | 4 | C | Direct | ||
| 0 | No | 4 | C | Direct |
Footnotes
- Each share of the issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock automatically converted into one (1) share of the issuer's Common Stock immediately upon the closing of the issuer's initial public offering on March 3, 2020.
- The shares are held directly by Frazier Life Sciences IX, L.P. FHMLS IX, L.P. is the general partner of Frazier Life Sciences IX, L.P. FHMLS IX, L.L.C. is the general partner of FHMLS IX, L.P. Patrick J. Heron and James N. Topper are the managing members of FHMLS IX, L.L.C. and share voting and dispositive power over the shares held by Frazier Life Sciences IX, L.P. Each of Mr. Heron, Mr. Topper, FHMLS IX, L.P. and FHMLS IX, L.L.C. disclaim beneficial ownership of the shares held by Frazier Life Sciences IX, L.P., except to the extent of his or its pecuniary interest therein, if any.
Billionaire Hedge Funds
